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Background: Gain-of-function mutations of the nociceptive voltage-gated sodium channel Nav1.7 lead to inherited
pain syndromes, such as paroxysmal extreme pain disorder (PEPD). One characteristic of these mutations is slowed
fast-inactivation kinetics, which may give rise to resurgent sodium currents. It is long known that toxins from
Anemonia sulcata, such as ATX-II, slow fast inactivation and skin contact for example during diving leads to various
symptoms such as pain and itch. Here, we investigated if ATX-II induces resurgent currents in sensory neurons of
the dorsal root ganglion (DRGs) and how this may translate into human sensations.
Results: In large A-fiber related DRGs ATX-II (5 nM) enhances persistent and resurgent sodium currents, but failed
to do so in small C-fiber linked DRGs when investigated using the whole-cell patch-clamp technique. Resurgent
currents are thought to depend on the presence of the sodium channel β4-subunit. Using RT-qPCR experiments,
we show that small DRGs express significantly less β4 mRNA than large sensory neurons. With the β4-C-terminus
peptide in the pipette solution, it was possible to evoke resurgent currents in small DRGs and in Nav1.7 or Nav1.6
expressing HEK293/N1E115 cells, which were enhanced by the presence of extracellular ATX-II. When injected into
the skin of healthy volunteers, ATX-II induces painful and itch-like sensations which were abolished by mechanical
nerve block. Increase in superficial blood flow of the skin, measured by Laser doppler imaging is limited to the
injection site, so no axon reflex erythema as a correlate for C-fiber activation was detected.
Conclusion: ATX-II enhances persistent and resurgent sodium currents in large diameter DRGs, whereas small DRGs
depend on the addition of β4-peptide to the pipette recording solution for ATX-II to affect resurgent currents.
Mechanical A-fiber blockade abolishes all ATX-II effects in human skin (e.g. painful and itch-like paraesthesias),
suggesting that it mediates its effects mainly via activation of A-fibers.
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Figure 1 Example traces for the isolation of ATX-II enhanced
TTXs resurgent currents. Representative recordings from one large
diameter DRG neuron using the protocol shown in the upper panel
in a. (a) Traces recorded under control conditions without any toxin
present. (b) Traces recorded with 5nM ATX-II in the extracellular
recording solution. (c) shows recordings in the presence of 5 nM
ATX-II and TTX with no resurgent currents present. This trace was
subsequently subtracted from the ones shown in (a) and (b),
revealing the TTXs resurgent current pre (d) and post (e) application
of ATX-II, respectively. Eight out of eight large DRGs recorded at
22°C showed resurgent currents.
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The voltage-gated sodium channel subtype Nav1.7 plays
a major role in human pain perception: Patients who
lack functional Nav1.7 due to loss of function mutations
are incapable of feeling pain [1]. Patients carrying muta-
tions that lead to a gain of function of Nav1.7, on the
other hand, suffer from inherited pain syndromes, such
as the paroxysmal extreme pain disorder (PEPD, [2,3]).
In humans nine different subtypes of sodium channels
are expressed (Nav1.1 to Nav1.9), and six of them can be
found in sensory neurons (the tetrodotoxin sensitive
(TTXs) channels Nav1.1, 1.2, 1.3, 1.6 and 1.7, and the
TTX resistant (TTXr) channels Nav1.8 and 1.9).
Voltage-gated sodium channels are responsible for ac-
tion potential (AP) initiation in neurons and propagation
along axons [4]. Upon depolarization, sodium channels
open rapidly and inactivate within milliseconds, support-
ing membrane repolarization. On a molecular level, the
inactivation gate, which is situated on the linker between
the channel’s domains III and IV, swings into the open
pore and thereby blocks the permeation pathway for so-
dium ions [5]. An endogenous blocking particle, most
probably the C-terminus of the β4-subunit, may interfere
with this process, allowing the induction of resurgent cur-
rents [6], that increase neuronal excitability. Resurgent
currents are enhanced by conditions that slow fast inacti-
vation, as this increases the possibility for the blocking
particle to bind to the open channel. PEPD mutations
have a slowed fast inactivation and exhibit resurgent cur-
rents when expressed in DRGs [7]. This also holds for
HEK293 cells, provided that parts of the β4-subunit are
present in the intracellular solution [8,9].
Several toxins are known to interact with the gating
properties of voltage-gated sodium channels. ATX-II from
the sea anemone Anemonia sulcata was shown to slow
fast inactivation [10-12], and is therefore likely to induce
resurgent currents. When divers get in contact with sea
anemone, they report symptoms such as pain and itch. In
order to learn more about the potentially painful effects
of ATX-II on nociceptive sodium channel gating, we
investigated small and large diameter DRGs with the
whole-cell patch-clamp method. We can indeed show
that ATX-II enhances persistent and resurgent currents
in large diameter sensory neurons of the dorsal root gan-
glia (DRGs), which are thought to be linked to A-fibers of
peripheral nerves [13]. Small DRGs on the other hand,
which give rise to C-fibers, were not reported to display
any endogenous resurgent currents [14] and also applica-
tion of ATX-II failed to induce them. In order to correlate
our findings with human sensations, we injected small
amounts of ATX-II intradermally and examined the
evoked sensations in healthy human subjects. Our results
suggest that ATX-II may selectively activate A-fibers and
thereby mediate itch-like sensations and pain.Results
ATX-II increases resurgent and persistent currents
in large diameter DRGs
Large DRGs are known to display resurgent currents
[14]. As ATX-II impairs fast inactivation of sodium
channels [10,15,16], we set out to test whether it might
favor binding of the blocking particle and therefore en-
hance resurgent currents in DRGs. Upon repolarization
following a strong depolarizing pulse (to +30 mV) we
evoked resurgent currents in large DRGs that are clearly
distinguishable from tail currents by their slower activa-
tion and decay kinetics (Figure 1). At the end of the
500 ms repolarizing pulse, a persistent current compo-
nent was obvious (Figure 2a).
Resurgent currents were clearly increased in large
DRGs by addition of 5 nM ATX-II to the bath solution
(Figures 1 and 2a and b). As expected for a fast binding
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Figure 2 ATX-II induces resurgent currents in large diameter DRGs. (a) Voltage protocol and representative TTXs resurgent current traces
(black traces represent recordings at −45 mV) pre and post application of ATX-II in large diameter DRGs. Lower lane shows an overlay of traces
recorded pre and post ATX-II at −45 mV on a longer time scale. Arrows illustrate resurgent current and the region of mean persistent current
measurements. (b) Peak resurgent current as a function of voltage recorded at 22°C (n = 8). Total current (TTXs and TTXr, black circles), peaked
around −40 mV. Absolute total resurgent current (black circles) increased following application of 5 nM ATX-II (pink circles), and is mostly carried
by TTXs sodium currents (square symbols). The overall resurgent current was dramatically reduced by application of TTX (grey circles). (c) TTXs
resurgent current at 22°C (filled squares, n = 8) and 30°C (open squares, n = 14) is increased by application of ATX-II. Data points for 22°C are the
same as in (b) and shown for better comparison. (d) Mean persistent TTXs current (black squares, determined as shown in (a) lower panel) is
increased by ATX-II exposure (pink squares), whereas an increase in temperature has a smaller effect (22°C: filled squares, n = 8; 30°C: open
squares, n = 14). (e) Corrected TTXs resurgent current amplitudes as a function of voltage. Corrected traces were obtained by subtraction of TTXs
persistent current (shown in d) from TTXs peak resurgent current (shown in c) of each trace. At 22°C (filled symbols, n = 8) as well as at 30°C
(open symbols, n = 14) corrected resurgent currents are increased by ATX-II application. * p < 0.05, paired-sample T-test.
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few seconds, and we started recordings 1.5 min after
toxin application. Although ATX-II most likely increases
tail current as well, the slow kinetics of the ATX-II
induced current strongly suggests that ATX-II affects re-
surgent currents. TTX application reduced the total in-
ward current, and resurgent currents were abolished,
leaving only a marginal component (Figure 2b, grey cir-
cles). This indicates that resurgent currents are mainly
mediated by TTXs channel-subtypes. Therefore in thefollowing we isolated the TTXs sodium current by sub-
tracting the TTXr component (Figure 1).
We have previously shown that resurgent currents are
modified by the anticancer agent oxaliplatin in a
temperature dependent manner [17], and therefore tested
the effect of ATX-II on large diameter DRGs at 22°C and
30°C. Native TTXs resurgent or persistent currents were
not affected by temperature (Figure 2c and d, black and
white symbols). In the presence of ATX-II resurgent and
persistent currents tended to be larger at 30°C compared
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current densities: At 30°C, resurgent 92.2± 8.8 pA/pF,
persistent 37.4± 5.9 pA/pF, n = 14. At 22°C, resurgent
67.6± 9.9 pA/pF, persistent 20.4 ± 3.4 pA/pF, n = 8). From
Figure 2c the activation of the TTXs resurgent current
seems to be shifted to more negative potentials. However,
when calculated as relative conductance, this shift is no
longer detectable, suggesting that ATX-II solely enhances
resurgent currents, and does not alter its voltage-
dependence (Additional file 1: Figure S1).
ATX-II induces a prominent persistent current com-
ponent (Figure 2d), which may also affect the absolute
resurgent current amplitude. In order to evaluate the
ATX-II induced resurgent current amplitude in isolation,
we subtracted the mean persistent currents measured at
the end of the hyperpolarizing pulse from the peak in-
ward resurgent currents (see Figure 2a, lower traces). It
is evident, that a large component of the ATX-II effect is
due to an increase in persistent currents (Figure 2e com-
pared to Figure 2c). Nonetheless, corrected resurgent
currents (Figure 2e) are enhanced by ATX-II at both
temperatures tested (corrected resurgent current dens-
ities: 22°C pre: 35.5 ± 7.7 pA/pF; 22°C post: 57.0 ± 9.7large DRGs
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Steady-state fast inactivation of TTXs Navs in large
DRGs was shifted to more hyperpolarized potentials by
application of 5 nM ATX-II (Vhalf pre: -62.5 ± 1.2 mV,
post: -66.8 ± 1.2 mV, p < 0.001), as was the voltage de-
pendence of activation (Vhalf pre: -42.6 ± 1.1 mV, post:
-45.0 ± 0.9 mV, p < 0.01, Additional file 2: Figure S2a).
Surprisingly, a double-exponential fit to current decay
did not reveal significant changes when cells were
exposed to 5 nM ATX-II (Additional file 2: Figure S2b
and 2c). It may be that the changes remained small and
under our detection level, or that the underlying TTXs
channel subtypes are affected to a different extent.
ATX-II is unable to induce resurgent currents in small
DRGs
Up to now, no resurgent currents were described in small
diameter DRGs [14], and accordingly, we were unable to
detect any significant resurgent or persistent sodium cur-
rents in sensory neurons <25 μm (Figure 3a, upper traces,
for criteria for resurgent current detection see Methods
section). Addition of 5 nM ATX-II at 22°C or 30°C didTTXs persistent current
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currents (Figure 3b and c), although application of higher
concentrations, such as 25 nM induced a significant per-
sistent current in small DRG neurons (Additional file 3:
Figure S3). In contrast, voltage dependence of activation
and steady-state fast inactivation were shifted to more
negative potentials by 5 nM ATX-II (Activation: Vhalf pre:
-34.9± 1.0 mV, post: -40.7± 0.8 mV, steady-state fast in-
activation: Vhalf pre: -74.7± 2.4 mV, post: -80.5± 2.0 mV,
both p <0.001, Additional file 2: Figure S2a). A double ex-
ponential fit of current decay did not reveal any significant
changes when 5 nM ATX-II was applied to small DRGs
(see Additional file 2: Figure S2b and c). Our results sug-
gest that either small DRGs possess a set of sodium chan-
nels less sensitive to ATX-II, or that they express
insufficient amounts of the key components necessary for
the generation of resurgent currents. Resurgent currents
are thought to rely on the presence of an endogenous
blocking particle, which is most likely formed by the β4-
subunit, or at least parts of it [9].
Different types of DRGs were suggested to express
separate sets of sodium channel α- and β-subunits. In
situ hybridization and functional studies suggest that
Nav1.6 is predominantly found in large DRGs, whereas
Nav1.7 is reported to be functionally responsible for APTTXs with peptide
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of small DRGs [13]. β4 was described to be expressed at
a higher level in large diameter DRGs than in small [21].
In order to assess the expression of β4, Nav1.6 and
Nav1.7 in our preparation, we sorted dissociated DRGs
according to their size using FACS (see Methods). The
mRNA of size-sorted cells was isolated and we con-
firmed by RT-qPCR that in our preparation mRNA of
the β4-subunit is twice as strongly expressed in large
compared to small DRGs (Figure 3d). Nav1.6 mRNA
levels were more prevalent in large DRGs compared to
small DRGs whereas Nav1.7 mRNA was expressed at
comparable levels between the two groups. Thus, the
lack of resurgent currents in small DRGs might be due
to insufficient amounts of β4-subunits, as there is evi-
dence that the β4-subunit plays an important role in the
generation of resurgent currents [9,22].
We added a 14 amino acid peptide of the β4-subunit
C-terminus to the pipette solution, which enables the
recording of resurgent currents in heterologously
expressed sodium channels [8,23,24]. With the β4-
peptide added to the pipette solution, we were able to
record very small, hardly detectable, resurgent currents
in one small diameter DRG out of four (example trace
in Figure 4a, upper lane). When 5 nM ATX-II wasc
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recorded from four out of six cells. The amount of
induced persistent current was small, and correction for
it (compare to Figure 2e) still revealed a robust enhance-
ment of resurgent currents in small diameter DRGs by
ATX-II when the β4-peptide was added to the pipette
solution (Figure 4c).
Nav1.7 and Nav1.6-mediated resurgent currents are
enhanced by extracellular ATX-II
Our results suggest that it is the amount of β4 present
in the cell that determines whether ATX-II can increase
resurgent currents in DRGs or not. mRNA of Nav1.7 in
small DRGs is three to seven times more strongly
expressed than Nav1.6, and its expression level does not
vary much between large and small DRGs (Figure 3d,
[18]). We used a HEK293 cell line stably expressing
Nav1.7 and tested for resurgent currents (Figure 5, left
column). Up to date no resurgent currents could be
evoked when Nav1.7 was transfected either alone or in
combination with the β4-subunit, also shown before for
Nav1.1 and Nav1.6 [17,23,25]. We were able to record
very small resurgent currents in three out of 15 Nav1.7
expressing cells (20.0%) when the β4-peptide was added
to the pipette solution. With ATX-II in the recording so-
lution, about half of the cells exhibited resurgent cur-
rents (17 out of 32, 53.1%), and their mean resurgent
currents were larger than that without ATX-II (Figure 5).
ATX-II also increased persistent currents of these cells,
but correction for it did not alter the ATX-II effect on
Nav1.7 mediated resurgent currents much (Figure 5c, d).
Our RT-qPCR data indicate that Nav1.6 shares its ex-
pression pattern between large and small DRGs with β4
and this Nav subtype is linked to resurgent currents in the
literature [26-28]. We heterologously expressed Nav1.6 in
N1E115 cells and tested for its ATX-II sensitivity with the
β4-peptide present in the pipette (Figure 5, right column).
In seven out of 17 cells (41.2%) a resurgent current was
detectable without ATX-II, which increased significantly
when the toxin was applied (twelve cells out of 17, 70.6%).
Although the persistent current was enhanced in the pres-
ence of ATX-II, too, correction for it still revealed a sig-
nificant increase of ATX-II induced resurgent currents in
Nav1.6 (Figure 5d), which is in accordance with our find-
ings in large DRGs (Figure 2).
Like the resurgent currents, the inactivation kinetics of
Nav1.6 seem to be more sensitive to ATX-II than those
of Nav1.7 (Figure 6a). A double exponential fit of
current decline revealed that in both channels τ 2, the
slower time constant is affected by application of 5 nM
ATX-II (Figure 6c). Unlike Nav1.7, the relative A1 of
Nav1.6 is significantly decreased (Figure 6b), thereby in-
creasing the importance of the slow component in
current decay. Slowing the process of inactivation mayincrease the likelihood of the β4-peptide to bind to the
open channel.
In the presence of the β4-peptide, ATX-II shifts the acti-
vation of Nav1.6 and Nav1.7 in opposite directions (Vhalf
for Nav1.6 pre: -18.2 ± 1.1 mV, post: -20.6 ± 1.2 mV,
n= 17; for Nav1.7 control: -19.4± 1.6 mV, n= 8, ATX-II:
-14.8 ± 1.1 mV, n= 22, p < 0.05, Figure 6a). This opposite
effect of ATX-II on Navs suggests that the shift of activa-
tion that we see in small DRGs (Additional file 2: Figure
S2a) may be due to ATX-II effects on other Nav subtypes
than Nav1.7, or due to the absence of the interacting β4
subunit. The slope of activation remained unchanged
(for Nav1.7 control: 6.75 ± 0.41, ATX-II: 7.4 ± 0.29, for
Nav1.6 control: 6.3 ± 0.2 ATX-II: 5.9 ± 0.3, both not
significantly different).
Steady-state fast inactivation of Nav1.6 and Nav1.7
remained largely unaffected by 5 nM ATX-II, and only the
slope of Nav1.6 fast inactivation became marginally less
steep (Vhalf for Nav1.7 control: -75.3± 2.9 mV, ATX-II:
-70.8 ± 1.5 mV, for Nav1.6 control: -64.9± 1.2 mV, ATX-II:
-64.5 ± 1.2 mV, both not significantly different. Slope for
Nav1.7 control: 7.0 ± 0.6, ATX-II: 6.6 ± 0.5, n = 3–8, for
Nav1.6 control: 6.3 ± 0.2, ATX-II: 5.9 ± 0.3, n = 17,
Figure 6a).
Small DRGs give rise to C-fibers, whereas large DRGs
were reported to be linked to A-fibers [13]. As 5 nM
ATX-II affected large DRGs and did not induce a resur-
gent current in small DRGs, we predict that in humans
ATX-II should preferentially affect A-fiber-mediated
somatosensation, while leaving C-fiber-dependent sensa-
tions largely intact. In order to test for ATX-II evoked
sensations, we performed a psychophysical trial with
healthy volunteers.
Human sensory response to intradermally injected ATX-II
is mediated by A-fibers
Upon intradermal injection of ATX-II on the forearm,
all subjects reported unpleasant and painful prickling or
tingling sensations, which were not of burning character.
These sensations were described to be different to C-
fiber mediated pain as it is for example reported follow-
ing capsaicin injection. The pain was also described as
"pulsating" or “cold snowflakes which are hitting the
skin”. In parallel to pain subjects reported itch-like sen-
sations, which were characterized as "if the skin was
tickled with a thin hair”, “an insect walked on the skin”, or
“liquids dropped on the skin”. Subjects were asked to rate
their sensations on a numerical rating scale (NRS, 0–10,
with 0 being no pain and 10 the worst imaginable pain)
and mean NRS ratings were 1.3 ± 0.1 for both, pain
and itch-like sensations in the first 10 min after the
injection (Figure 7a and b show representative exam-
ples each), and declined within ~10 min after the end
of the experiment. A control group was injected with
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Figure 5 ATX-II induces resurgent currents in Nav1.7 and Nav1.6 expressing cells when β4-peptide is present in the pipette solution.
(a) Voltage protocol (top panel) and representative current recordings with the β4-peptide added to the pipette solution (lower panel): left: stable
HEK cell line expressing Nav1.7; right: Nav1.6 transfected N1E115 cells. An overlay of recordings under control conditions and ATX-II (5 nM)
exposure at −20 mV (for Nav1.7) and −10 mV (for Nav1.6) is shown. (b) Peak current within the first 10 ms after repolarization of control (black
symbols) and ATX-II exposed cells (pink symbols, left: Nav1.7, n = 15,17; right: Nav1.6, n = 11,11 for control and ATX-II, respectively). Resurgent
currents are enhanced by the presence of ATX-II, when the β4-peptide is present in the pipette solution. (c) Mean persistent currents at the end
of the repolarizing pulse are affected in Nav1.6 (right) and in Nav1.7 (left) by addition of extracellular ATX-II to the bath solution (pink symbols).
(d) The increase of resurgent current is not due to a persistent current component, as subtraction of the persistent current from peak current
reveals a clear corrected resurgent current component in both Nav1.7 (left) and Nav1.6 (right) expressing cells. * p < 0.05, independent-sample T-
test for Nav1.7, paired-sample T-test for Nav1.6.
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itch or pain, apart from a small immediate short last-
ing pain which was most likely evoked by mechanical
irritation due to the injection needle (mean < 0.3 on
the NRS, n = 9, 3 male and 6 female).The AUCs of pain and itch ratings were significantly
higher in the ATX-II-injected group compared to the con-
trols (Figure 7a and b, n = 6 each, p < 0.004; p < 0.008, re-
spectively, Mann Whitney U-test). Static or mechanical
allodynia was absent (tested by gentle pressure with a
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injection of ATX-II, not shown). NRS pain ratings (0–10)
to a 7 s lasting heat stimulus of 47°C were unchanged
compared to preinjection conditions (n= 6, not shown).
A typical symptom of C-fiber activation is the axon re-
flex flare [29]. Following application of ATX-II, laser
Doppler scanning detected a small increase in local
blood flow due to the injection itself, but there was no
widespread axon reflex flare (n = 6, Figure 7e, blue
squares). A classical axon reflex erythema evoked by his-
tamine (1% applied by iontophoresis) is shown for com-
parison (Figure 7e, white squares). In humans, histamine
activates the group of mechano-insensitive C-fibers,
which release calcitonine gene-related peptide (CGRP)
upon activation causing widespread vasodilatation [30]
when evoked action potentials are antidromically propa-
gated into branching nerve endings.
Our patch-clamp experiments suggest that ATX-II pre-
ferably activates A-fibers (connected to large diameterDRGs), whereas its effect on C-fibers (linked to small
DRGs) is small or negligible. For further validation of this
hypothesis a mechanical differential nerve block was ap-
plied prior to ATX-II injection, which mainly affects A-
fibers [31,32]. During differential nerve block, no pain
(apart from a brief injection pain) or itch-like sensations
were reported, revealing a mean AUC during nerve block
of 1.3 ± 0.9 and 0.0 ± 0.0, respectively (hatched squares
Figure 7c and d). After removal of the nerve block pain
and itch-like sensations immediately arose within seconds
and were described as “identical” to those following ATX-
II injection without a nerve block by volunteers who had
undergone this procedure before. This indicates that
mechanical block successfully interfered with ATX-II
evoked sensations.
NRS curves for pain and itch were recorded for
10 min following removal of the differential nerve block,
and subjects reported spontaneous pain (Figure 7c,
blue squares). AUC values for pain ratings post nerve
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Figure 7 Intradermal injections of ATX-II induces pain and an itch-like sensations in human volunteers. (a) Pain assessment (on a
numerical rating scale, NRS 0–10) as a function of time for a subject following injection of saline solution without (control) or with ATX-II. Under
control conditions (white symbols) only a short lasting pain is evoked immediately after the injection in agreement with mechanical irritation,
whereas ATX-II injection (blue symbols) leads to distinctly augmented ratings. The right panel shows the mean area under the curve (AUC) for
n = 6 volunteers (* p < 0.05). (b) Assessment of itch-like sensations on a NRS ranging from 0–10 following injection (sensation rated as 3 is
equivalent to desire to scratch) of one representative subject. While under control conditions (white symbols) no itch is induced following
injection, ATX-II (red symbols) evoked itch-like sensations, also reflected in a larger AUC (right, * p < 0.05). (c) and (d) Pain (blue squares and bar)
and itch (red squares and bar) ratings as a function of time following compression induced nerve block. After 30–40 min of A-fiber block ATX-II
was injected and sensations were rated during 10 min (hatched squares). While no pain and itch is evoked by ATX-II under nerve block
conditions, pain (blue symbols) and itch (red symbols) recur fast after removal of the block. AUCs of pain ratings increased significantly after
removal of the block (* p < 0.05). (e) Area of increased blood flow measured by laser doppler imaging every 2 min following ATX-II injection (blue
squares, n = 6) shows hardly any increase in superficial blood flow. For comparison, a typical histamine-induced axon reflex erythema mediated
by activation of C-fibers and concomitant CGRP release is shown (white squares). Right: Example images taken 4 min after application of
substances. (f) Assessment of cold-evoked (0°C, 7 s) pain (NRS 0–10) before (white bar) and during nerve block (hatched bars). 10 min after
injection of ATX-II cold-evoked pain is rated and the nerve block removed. Cold-evoked pain 20 and 30 min after injection of ATX-II significantly
increases following removal of the nerve block (* p < 0.05).
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(n= 6, p < 0.03; Wilcoxon matched pairs test, Figure 7c,
bar graph). However, no itch-like sensations were reported
by 50% of the volunteers following ATX-II injection after
removal of the nerve block, indicative of a faster decline of
the itch-like component of ATX-II evoked responses over
time compared to pain. This further suggests that ATX-II
mediates its effects in humans via A-fibers.
NRS pain ratings in response to a cold stimulus (7 s, 0°C)
were used to determine progression of the differential nerve
block. Mean ratings before treatment were 0.1±0.1, and
cold sensation was lost under nerve compression be-
fore injection of ATX-II (Figure 7f, white bar). During the
differential nerve block only very little cold evoked
pain was recorded after ATX-II injection (Figure 7f,blue hatched bar). Removal of block, however, lead to a sig-
nificantly increased cold evoked pain rating and discomfort-
ing mechanical sensations 20 and 30 min after ATX-II
injection compared to basal ratings (both p < 0.002*,
ANOVA (p< 0.001), following HSD post hoc test). This
phenomenon was limited to the site of ATX-II injec-
tion within the area of the differential nerve block. The
strongly enhanced cold evoked pain following ATX-II in-
jection most likely depends on A-fiber activation, as it was
abolished by differential nerve compression.
Discussion
Here we show, that ATX-II enhances persistent and re-
surgent currents in large diameter DRGs (Figure 2), but
fails to do so in small DRGs (Figure 3). This is most
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these small neurons (Figure 3d), which is thought to be
essential for the generation of resurgent currents.
Addition of the β4-peptide to the pipette solution
enabled us to record ATX-II-inducible resurgent cur-
rents in small DRGs and HEK cells stably expressing
Nav1.7. Large DRGs are linked to A-fibers, and support-
ing our in vitro findings, injection of small amounts of
ATX-II into the skin of human volunteers evoked
responses in accordance with A-fiber activation.
Large DRGs exhibit endogenous resurgent currents
that can be enhanced by ATX-II. This is not the case for
small DRGs, even though small DRGs are known to ex-
press ATX-II sensitive sodium channels (such as Nav1.1,
Nav1.2 and Nav1.6 [16,18,20,33]). Mice lacking func-
tional Nav1.6 (med mice) display reduced resurgent cur-
rents [34], and there is evidence, that the interaction of
the β4-subunit with sodium channels is a major precon-
dition for resurgent currents to occur (e.g. [35]). Our
RT-qPCR data of the FACS sorted DRGs show that large
DRGs have higher levels of β4 mRNA than small neu-
rons (Figure 3d and [21,34]). Considering the primer
efficiencies, DRGs of both sizes have ~5 times more β4
than Nav1.6 (5 and 4.5 times for small and large DRGs,
respectively), which would be ample for a simple 1:1
interaction. In small DRGs Nav1.7 is expressed ~7 times
stronger than Nav1.6, making it more likely for the β4-
subunit to interact with Nav1.7 than with Nav1.6 in
small DRGs. It may be possible that Nav1.7 has a lower
affinity for β4, and therefore needs higher concentrations
for a successful interaction, which could be provided
by addition of β4-peptide to the recording solution
(Figures 4 and 5).
Compared to Nav1.7, Nav1.6 shows resurgent currents
in a larger population of cells under control condition
with the peptide in the pipette (53.1% vs. 26.7%, respect-
ively). Nevertheless it might be hard to compare chan-
nels expressed in a cell line and draw conclusions to the
extent of its modification in its native environment as
for example in DRGs. If the peptide was present, seven
out of 17 cells transfected with Nav1.6 show resurgent
currents, whereas only three out of 15 cells expressing
Nav1.7 showed these currents by themselves. Although
the cellular background may play a role, these data sug-
gest that Nav1.6 is more prone to interact with the β4-
peptide and to produce resurgent currents. It may be
possible that the amount of endogenous β4-subunit in
small DRGs is simply not sufficient for a robust inter-
action with any endogenous TTXs sodium channel
expressed in these cells and therefore no resurgent cur-
rents can be recorded.
An increase in ATX-II concentration up to 25 nM failed
to induce resurgent currents in small DRGs (Additional
file 3: Figure S3), but only enhanced persistent currents.This finding is comparable to that of the application of
the wasp venom β-Pompilidotoxin to CA3 neurons [36],
which induced tail and persistent, but no resurgent cur-
rents unless the β4-peptide was present in the recording
pipette. Our data suggest that small DRGs share this char-
acteristic with CA3 neurons.
An enhanced persistent current may very well increase
excitability by its own, and indeed application of 1 μM
ATX-II to IB4 negative small DRG neurons resulted in a
broader AP [37]. Interestingly, ATX-II sensitivity seems
to be distinct between the different subsets of small
DRG neurons, as IB4 positive small DRGs did not
change their AP properties in response to ATX-II appli-
cation. The toxin concentrations that we used in our
study induced a shift of TTXs current activation and
steady-state fast inactivation (Additional file 2: Figure
S2), but failed to have effects on persistent or resurgent
currents (Figure 3). Therefore, it is likely that the toxin
concentrations used in our experiments remained below
threshold for an effect on persistent or resurgent cur-
rents in small DRGs, and that in small DRGs persistent
and resurgent currents are less sensitive to small
amounts of ATX-II than activation and steady-state fast
inactivation.
Surprisingly, mRNA for Nav1.7 is expressed in large
and small DRGs at comparable levels (Figure 3d, [18]).
Patients with the inherited pain syndromes erythrome-
lalgia and PEPD, both due to mutations in Nav1.7, de-
scribe their pain mainly as burning - a typical C-fiber
associated characteristic. As Nav1.7 seems to be evenly
distributed between large and small DRGs, it is likely
that associated proteins, such as the β4-subunit, or cell-
background specific channel modifications, may play a
major role in the generation of Nav1.7 related pain. The
discrepancy may also be due to species differences: We
investigated DRGs from mice, but erythromelalgia and
PEPD manifest themselves in humans. Knowledge about
the developmental regulation of β4 expression is still
lacking. PEPD mutations of Nav1.7 were shown to in-
duce resurgent currents by slowing fast inactivation
[7,8]. We show in this study, however, that even in the
presence of ATX-II no resurgent current could be
evoked in small DRGs or Nav1.7 expressed in HEK293
cells unless the β4-peptide is present. Patients with
PEPD are severely affected during their first year of life
but symptoms become somewhat milder later in life. It
remains speculative if this might be due to a down regu-
lation of β4 with age, for which data are currently not
available.
ATX-II alone was unable to induce resurgent currents
in heterologously transfected Nav1.7 or Nav1.6, which
was reported before [38]. Up to now, only one toxin, the
β-scorpion peptide Cn2, was able to induce resurgent
currents in a heterologous expression system without
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These currents were enhanced by ATX-II. This finding
suggests that sodium channels need some kind of modi-
fication, like treatment with Cn2 or potentially a disease
causing mutation, such as PEPD, in order to be capable
to produce resurgent currents.
In the 70s and early 80s of the last century, it was
observed that ATX-II broadens the AP of crustea per-
ipheral axons, and not much later it became evident that
this was due to a slowing of inactivation properties of
voltage-gated sodium channels [10,15,39,40]. When ap-
plied to large DRGs in high concentrations (10 μM), it
significantly slowed τh of Nav current inactivation [41].
Here, we used concentrations that are an order of mag-
nitude lower and although we used recombinant ATX-II
(purity >98%), which may be more specific in its effects
than purified ATX-II, the effect on the peak current decay
time constants was no longer detectable (Additional file 2:
Figure S2 b,c), but nevertheless resurgent currents were
altered significantly. Also, we observed shifts in activation
and steady-state fast inactivation. This suggests that even
though the effects on inactivation kinetics were small, the
concentration of ATX was high enough to enhance resur-
gent currents, which in large DRGs seem very sensitive to
even small channel alterations. Higher concentrations
of ATX-II evoked resurgent currents in large DRGs,
which were too large to be properly recorded under
our conditions. This suggests that 5 nM ATX-II is a con-
centration at which effects may be evoked in large, but
not in small DRGs, thereby allowing a separation of the
two groups.
Molecular studies discriminated between sodium chan-
nel subtypes in heterologous expression systems for their
sensitivity to ATX-II, showing that mainly Nav1.1, Nav1.2
and Nav1.6 are modified at very low concentrations
[16,33,38]. These three channels can be found in large and
small DRGs [18,20] and in large, but not small DRGs their
modification by ATX-II enhances resurgent currents.
ATX-II slows inactivation kinetics for both channels
investigated in this study: Nav1.6, which is supposed to
be the main carrier of the AP in large DRGs and Nav1.7,
which is suggested to play this role in small DRGs [19].
The slower fast inactivation occurs the higher the prob-
ability is for a potential open channel blocker to interact
with the pore. Consequently, in the presence of the β4-
peptide, we were able to significantly increase resurgent
currents in both channel subtypes (Figure 5). These
experiments suggest that two requirements are necessary
for ATX-II to increase resurgent currents: I) an ATX-II
sensitive sodium channel (such as Nav1.7 or Nav1.6, but
also other subtypes, [16,33,38]) and II) the availability of
an intracellular open channel blocker. Both seem to be
present in large DRGs, whereas our experiments suggest
that small DRGs are missing at least one of thecomponents. As the TTXs sodium channels that were
shown to be expressed in small DRGs are almost all sen-
sitive to ATX-II (Nav1.1, 2, 6 and 7, [16,18,20], Figures 5
and 6), even at the low concentrations that we used
here, it is quite likely that small DRGs are lacking suffi-
cient open channel blocker. Accordingly, when we added
the β4-peptide to the intracellular recording solution, re-
surgent currents were present in small DRGs (Figure 4).
Recently we showed that the anticancer agent oxalipla-
tin selectively enhances persistent and resurgent cur-
rents in large diameter DRGs at low temperatures [17].
Oxaliplatin is highly effective but unfortunately has dose
limiting side-effects: acute and chronic neuropathies,
which are both characterized by cold evoked very un-
pleasant dysaesthesias. These sensations are similar to
those experienced by the subjects of the present study
following intradermal ATX-II injection. Besides an
increased cold perception 20 and 30 min after ATX-II
injection a pricking sensation outlasting the cold stimu-
lus was observed (see Figure 6f ), indicating ongoing ac-
tivity in the affected nerve fibers.
ATX-II did not display a marked temperature depend-
ence in its enhancement of resurgent or persistent cur-
rents, which is in contrast to oxaliplatin (Figure 2 and
[17]). Low temperatures induce a general increase in
membrane resistance, which would then allow a small
depolarizing current, like resurgent currents, to be po-
tentially sufficient to initiate a following AP. This may
explain why the subjects report cold enhanced sensa-
tions after ATX-II injection (Figure 7f ); even though re-
surgent currents were not significantly different at 22°C
compared to 30°C (Figure 2).
Oxaliplatin failed to affect C-fibers or small diameter
DRGs, suggesting that this drug, too, relies on the pres-
ence of the β4-subunit for its effects, or displays some
degree of subtype specificity. The presence or absence of
the endogenous blocking particle might thus render cer-
tain types of neurons susceptible for activation by toxins
or drugs which act via voltage-gated sodium channels.
Thus, focusing only on specific sodium channel subtypes
for the treatment e.g. of pain might not be reaching far
enough, but the channels functions in their cellular con-
text need to be considered.
Pain sensations in vivo may be transmitted via two
main types of fibers: the myelinated fast conducting A-
fibers, which are connected to large DRGs, and the
slower and unmyelinated C-fibers which are linked to
small diameter DRGs [13]. We have shown that low
concentrations of ATX-II activate large DRGs suggesting
that A-fibers convey the ATX-II evoked sensations of
the volunteers. Accordingly, mechanical nerve fiber
block abolished the ATX-II evoked sensations. Most
likely Aδ-fibers mediate the ATX-II induced pain symp-
toms but may also participate in the itch-like sensations.
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sertion of spicules from the pods of a cowhage plant in-
duce intense itching. Aδ-fibers seem to be involved in
transmitting this itch [42]. In some subjects, these sensa-
tions were markedly reduced by mechanical nerve block.
Intradermal injection of ATX-II, on the other hand,
evoked itch-like sensations, that were not described as
common itch, but unpleasant sensation, for which there
is no adequate word. “Tingling” was used by some sub-
jects, which maybe an overlapping sensation induced by
ATX-II and cowhage spicules. Apart from Aδ-fibers it is
likely that Aß-fibers are activated by ATX-II since sensa-
tions of mechanical character were described, such as
"like punctured by many thin needles". Possibly, the un-
common simultaneous activation of Aδ- and Aβ-fibers
may generate the unique ATX-II mediated perception.
In our in vivo experiments the A-fiber block may in-
duce paraesthesias itself, both during and upon recover-
ing from the block. However no paraesthesias were
described prior to and after ATX-II injection. Nonethe-
less, the reported sensations after ATX-II injections and
relief of block were comparable to those described when
no prior block was applied. The fact that cold evoked
pain, which strongly increased after removal of the
block, was closely restricted to the injection site
(Figure 7f ) argues against a general block-induced fiber
irritation. Nevertheless, an irritation of the fibers cannot
be ruled out, but we estimate it to be rather small in
comparison to the effects evoked by ATX-II alone.
Intradermal injection of ATX-II did not evoke a large
axon reflex flare (Figure 7e), arguing against a major acti-
vation of mechano-insensitive C-fibers [29]. Nevertheless,
mechano-sensitive C-fibers may mediate itch without the
induction of a major axon reflex flare [43,44]. Subjects
tested with cowhage spicules, which activate only
mechano-sensitive C-fibers vigorously and Aδ-fibers, re-
port quite different sensations than those injected with
ATX-II (burning pain, severe itch, which was also clearly
labeled as such). As mechano-sensitive C-fibers are also
resistant to differential nerve block and should therefore
have transmitted the ATX-II-mediated sensations, we
assume that mechano-sensitive C-fibers are not a major
target of ATX-II in humans.Conclusions
ATX-II enhances persistent and resurgent sodium cur-
rents in large diameter DRGs, whereas small DRGs de-
pend on the addition of β4-peptide to the pipette
recording solution for ATX-II to affect resurgent cur-
rents. Mechanical A-fiber blockade abolishes all ATX-II
effects in human skin (e.g. painful and itch-like sensa-
tions), suggesting that it mediates its effects mainly via
activation of large diameter A-fibers.We thus established low concentrations of ATX-II as a
tool for A-fiber activation, which induces pain and itch-
like symptoms in humans. We show that activation
mainly of A-fibers can be crucial for unpleasant pain
and itch-like sensations, which are not extremely painful
but could be distressing and reducing quality of life. We
also showed for the first time, that this toxin is able to
enhance resurgent currents of large DRGs, and of small
DRGs or heterologously expressed Nav1.7, when the β4-
peptide is present.
Methods
Animals and cell culture
Adult C3HeB/FeJ mice were anaesthetized with halothane
(Sigma- Aldrich GmbH, Steinheim, Germany) and
decapitated in accordance with ethical guidelines estab-
lished by German animal protection law, approved by the
animal protection committee of Regierung Mittelfranken,
Germany. After decapitation, the backbone was removed
rapidly and bisected longitudinally in ice-cold PBS (PAA
Laboratories GmBH, Pasching, Austria). DRGs were
removed, desheated, cleaned and enzymatically disso-
ciated in Dulbecco’s modified Eagle's Medium (DMEM,
Gibco-Life technologies, New York, USA) supplemented
with collagenase/protease for 45 min at 37°C. Cells were
mechanically triturated with small diameter pasteur pip-
ettes in TNB medium (Biochrom AG, Berlin, Germany).
Poly-D-Lysin (Sigma- Aldrich GmbH, Munich, Germany)
coated cover slips were loaded with the cell suspension
and after cells settled for 5–10 min TNB medium was
added. DRGs were incubated at 37°C and 5% CO2 until
experiments were performed at the following day. A
stable HEK293 cell line expressing hNav1.7 was cultured
under same conditions as DRGs in DMEM containing
500 mg/l G418 (Sigma-Aldrich GmbH). N1E115 neuro-
blastoma cells were maintained in DMEM medium
(Gibco-Life technologies) including 4.5 g/l Glucose, 10%
fetal bovine serum (Biochrom AG) and 1% Penicillin/
Streptomycin (PAA Laboratories GmbH). One day before
transfection N1E115 cells were plated on 3.5 cm dishes
(Falcon Corning, IBD) and transfected with Nanofectin
(PAA Laboratories GmbH) according to the manufac-
turers protocol using 1 μg mNav1.6R (TTX resistant
[45,46], in pCDNA3 and 0.5 μg EGFP-C1 (Clontech
Laboratories, Inc., Mountain View, USA) in order to de-
tect transfected cells via green fluorescence. Cells were
recorded 2 to 3 days after transfection.
Whole-cell patch-clamp recordings and electrophysiology
Whole-cell voltage clamp recordings were performed
using glass electrodes with tip resistances of 1.5- 2.0 MΩ,
manufactured with a DMZ puller (Zeitz Instruments
GmbH, Martinsried, Germany) and filled with an internal
solution comprising for DRGs (in mM): 140 CsF, 10 NaCl,
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with CsOH), for HEK cells (in mM): 135 CsCl, 5 NaCl,
2 MgCl2ATP, 10 HEPES and 5 EGTA (adjusted to pH
7.2 with CsOH) and for N1E115 cells (in mM): 125 CsCl,
5 NaCl, 2 Mg2ATP, 10 HEPES and 5 EGTA (adjusted
to pH 7.2 with CsOH). For recordings of activation
and steady-state fast inactivation of DRGs, an internal
solution with reduced sodium chloride (2 mM NaCl)
was used. The external bathing solution contained for
DRGs (in mM): 140 NaCl, 3 KCl, 1 MgCl2, 1 CaCl2,
10 HEPES, 5 Glucose, 20 TEA-Cl, 0.1 CdCl2 (adjusted
to pH 7.38 with NaOH), except for recordings of activa-
tion and steady-state fast inactivation, where NaCl
was reduced to 10 mM, substituted with CholinCl,
for HEK cells (in mM): 150 NaCl, 3 KCl, 2 MgCl2,
1.6 CaCl2, 0.4 CdCl2, 10 HEPES, 10 Glucose, 10 TEA-Cl
(pH= 7.4, adjusted with NaOH) and for N1E115 cells
(in mM): 145 NaCl, 4 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES,
10 Glucose, 10 TEA (adjusted to pH 7.4 with NaOH).
DRGs were classified according to their cell size as
large (> 35 μm) or small (< 25 μm). Size was measured
as the maximal diameter of the cells on a digital image
taken with an EC3 Camera (Leica, Wetzlar, Germany)
connected to a Leica- DCMI3000B microscope with a
64 x objective. Recordings were performed at either
room temperature (22 ± 1°C) or 30 ± 1°C, controlled by
an inline solution heater (Warner Instruments, Hamden,
USA) with a feedback thermocouple positioned less than
800 μm from the recorded cell. A HEKA EPC-10USB
(Lambrecht, Germany) was used for signal recording,
low-pass (10 kHz) filtering and digitizing (100 kHz).
For substance application the tip of a perfusion system
was positioned within 800 μm of the recorded DRG
neuron. Pipette potential was zeroed prior to seal forma-
tion and capacitive transients were compensated using
C-fast for pipette-capacity correction and subsequently
C-slow for cell-capacity compensation (PatchMaster,
HEKA, Lambrecht, Germany), the series resistance was
compensated by about 50% leaving a mean resistance of
3.8 ± 0.4 MΩ. The absolute peak current (pA) was divided
by the capacitance as determined by C-slow compensation
to obtain current densities. Leak pulses were applied
following the test pulse, and mean leak current was
subtracted digitally online corresponding to the P/4 test
pulse procedure.
To measure resurgent currents in DRGs an initial 20 ms
voltage step from a holding potential of −120 mV to
+30 mV was applied followed by 500 ms steps from
−80 mV to +25 mV (steps of 5 mV). In HEK293 cells a
12.5 ms depolarizing voltage step from −90 mV
to+30 mV preceded 50 ms steps from −80 mV to +20 mV
(steps of 10 mV). In N1E115 cells a 12.5 ms depolarizing
voltage step from −100 mV to +30 mV preceded 150 ms
steps from −90 mV to 0 mV (steps of 10 mV). Theresurgent current quantity was measured by detecting the
peak inward current following the pre-pulse. Persistent
current was determined as the mean current between
400 ms and 515 ms of the voltage protocol. To show resur-
gent current in isolation, not affected by the persistent
current, the latter was subtracted from the peak inward re-
surgent current to obtain the isolated resurgent current.
Persistent currents give rise to tail currents upon repo-
larization. Special care was taken in order not to confound
the slower activating and decaying resurgent currents with
tail currents. Especially its different voltage dependence
and kinetics allowed us to clearly discriminate between
the two. Current trajectories were only accepted as resur-
gent currents, if they clearly showed slowly rising and fall-
ing kinetics. In small diameter DRGs only tail currents
were visible under control conditions. By choosing the
relevant area for analysis, the peak inward resurgent cur-
rents could reliably be distinguished from tail currents, al-
though a small contamination cannot be excluded.
By subtracting the TTXr component (Figure 1) we
eliminated all TTXr currents including potassium and
calcium currents, which may also have tail currents. In
accordance with the literature, we were unable to detect
any TTXr resurgent currents ([14,17]).
Protocols were recorded while the bath perfusion was
constantly running, and repeated with ATX-II and TTX
in the external solution. TTXs components were isolated
by subtraction using Igor Pro software (Wavemetrics,
Lake Oswego, USA).
For recordings of DRGs and HEK293 cells with β4-
peptide in the internal pipette solution, cover slips were
incubated either in bath solution (control) or in bath so-
lution containing 5 nM rATX-II for 7 to 10 min before
begin of the protocol.
N1E115 cells intrinsically express TTX-sensitive
Nav1.1 and Nav1.2 (Benzinger et al., 1997), which were
suppressed in our experiments by adding 1 μM TTX
(Biotrend, Wangen/Zurich, Switzerland) to the bath so-
lution. Cells were mounted on the stage of Axiovert
40 fluorescense microscope (Zeiss, Jena, Germany).
TTX and ATX- II were applied using a gravity driven
Y-filament. Current signals were recorded in whole-cell
voltage-clamp mode at room temperature (22 ± 1°C).
Recordings were sampled at 20 kHz (low-pass filter
6 kHz) using an Multiclamp 700B amplifier in conjunc-
tion with a Digidata 1322A interface and pClamp10 soft-
ware (all from Molecular Devices, Sunnyvale, USA).
Electrodes were made as stated above. Access resistance
in whole-cell configuration was <4 MΩ before series re-
sistance compensation (≥75%).
FACS sorting and RT-qPCR
For each experiment 20–25 DRGs from two adult mice
each were pooled, filtered using a 100 μm cell strainer
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with both the nuclei labeling agent Hoechst 33258
(Invitrogen) and the avital marker 7AAD (Invitrogen,
labels all dead cells). Using a BD-FACSAria-II cell sorter
(Special Order System, BD Biosciences, Core Unit Cell
Sorting and Immunomonitoring Erlangen), neurons were
sorted for viability and size via their fluorescence and the
forward-side-scatter plot. In order to correlate the cat-
egories retrieved from the forward-side-scatter plots with
the actual cell size, sorted DRGs were cultured for 2–3 h
and the mean size of cells in each group was determined
via digital images taken with an EC3 Camera (Leica,
Wetzlar, Germany) connected to a Leica- DCMI3000B
microscope. Cells survived sorting well and had a healthy
appearance still several hours after FACS sorting. Cells
categorized as small had diameters ranging from 13 to
27 μm (the majority around 18 μm), whereas those cate-
gorized as large ranged from 27 μm to 43 μm (the major-
ity around 35 μm). Overall DRGs appeared slightly
smaller after FACS sorting compared to those cultivated
for 24 h, which might also be due to better attachment of
the cells to the cover slip in the latter case.
DRGs for each size-category were collected in PBS,
centrifuged and dissolved in Qiazol (Qiagen, Hilden,
Germany) for RNA isolation according to manufacturer’s
protocol. Potentially remaining DNA was digested with
RQ1 RNase-free DNase (Promega, Mannheim, Germany).
RNA concentration and purity was assessed with the
Nanodrop 2000c spectrophotometer (Peqlab, Erlangen,
Germany). RNA was subsequently reverse transcribed
with random hexamer primers using the cDNA synthesis
kit from Peqlab (Erlangen, Germany). Approximately 5 ng
of cDNA was added to the 2x SensiMix SYBR No-ROXTable 1 Primer pairs for real-time qPCR
Genes Accession number T
Scn8a (Nav1.6) [NCBI:NM_001077499]
for: 5’-CGTACTATTTGACGCAGAAAACTT-3’ E
rev: 5’-TCATGCTGAAGACTGAATGTATCA-3’ E
Scn9a (Nav1.7) [NCBI:NM_018852.2]
for: 5’-CAGCAAAGAGAGACGGAACC-3’ E
rev: 5’-TCTCCTCACACAGCCATCTG-3’ E
Scn4b (β4) [NCBI:NM_001013390]
for: 5’-CGAAACATCCAGGATTCTCAT-3’ E
rev: 5’-TCGTCTTCTCCTTGGTGGA-3’ E
Rpl13a [NCBI:NM_009438.5]
for: 5’-GCCTACCAGAAAGTTTGCTTACC-3’ E
rev: 5’-GGTACTTCCACCCGACCTC-3’ E
HPRT [NCBI:NM_013556]
for: 5’-TGGAAAGAATGTCTTGATTGTTG-3’ E
rev: 5’-CGAGAGGTCCTTTTCACCAG-3’ EKit (Peqlab, Erlangen, Germany) and mixed with 600 nM
of target primer for detection of either ß4-subunit
(Scn4b), Nav1.6 (Scn8a) or Nav1.7 (Scn9a) cDNA. To
avoid amplification of genomic DNA, exon-spanning pri-
mers were designed using Primer3Plus and analyzed by
IDT OligoAnalyzer 3.1. BLAST search was applied to
ensure specificity. Primer characteristics are shown in
Table 1. Reactions were performed in duplicates and car-
ried out using an Eppendorf realplex4 cycler (Eppendorf,
Hamburg, Germany). An initial denaturation step at 95°C
for 10 min was followed by 40 cycles of denaturation at
95°C for 15 s, annealing at 60°C for 30 s and extension at
72°C for 20 s. The generation of specific PCR pro-
ducts was confirmed by melting curve analysis and
gel electrophoresis. Differences in expression levels of
target genes in small and large neurons were deter-
mined using the ΔΔCq method. HPRT (hypoxanthine-
guanine phosphoribosyltransferase) and Rpl13a (ribosomal
protein L13a) were used as reference genes to gener-
ate a mean value for relative quantification of target
gene expression.
Psychophysics
Informed written consent was obtained from all subjects
(n = 9; 3 male and 6 female) in accordance with the
requirements of the Declaration of Helsinki and experi-
mental procedures for this study on human volunteers
were passed by the ethics committee of the University of
Erlangen. 70 μl of a sterile control solution (buffer) or
solution containing ATX-II (100 nM) were intradermally
injected at the volar forearm or to the innervation terri-
tory of the superficial radial nerve at the back of the
hand of the volunteer. Pain and itch-like sensations werearget sites Product size (bp) Efficiency
153 93%
xon 2- 3
xon 3- 4
142 95%
xon 18- 19
xon 19- 20
116 96%
xon 2-3
xon 3
59 99%
xon 6-7
xon 7-8
132 94%
xon 4-5
xon 7
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0 (no pain/itch sensation) to 10 (worst imaginable pain/
itch) in 15 s intervals for a period of 10 min. For thermal
stimulation metal rods of 1 cm2 in diameter were placed
in a preheated water bath at 47°C or ice water. Numer-
ical ratings to a 7 s lasting heat stimulus of 47°C and to
a 7 s lasting cold stimulus of 0°C were compared before
and after application of substances. The skin was tested
for static and dynamic mechanical allodynia by applying
gentle pressure with a cotton swab and stroking with a
fine brush. Laser-Doppler imaging (LDI, Moore, London,
UK) was used to record changes in superficial skin blood
flow. Two baseline scans of 0.5 mm spatial resolution on
a 10.8 cm x 7.0 cm area were taken, followed by scans
every 2.0 min starting right after the injections. The skin
blood flow was analyzed with MLDImg 3.08 software
(LDI, Moore, London, UK) and the area of vasodilata-
tion was defined as those pixels in which intensity
exceeded the mean of basal values plus two standard
deviations [47].
Differential conduction blockade of myelinated nerve
fibers was achieved by placing a padded sling connected
to a 2.5 kg weight at the proximal wrist of the volunteers
for 30–40 min to apply pressure to the superficial radial
nerve (also see [48]). Preferential A-fiber blockade
induced by nerve compression has been shown by
Torebjork et al. [31] and Mackenzie et al. [32] in micro-
neurography studies. In the case of the superficial radial
nerve the impaired A-fiber function with preserved
C-fiber function is limited to the autonomous zone
of the superficial radial nerve distal the metacarpopha-
langeal joints I + II. The progress of the differential block
following compression of the N. radialis superficialis was
monitored by decrease of touch and cold detection and
was considered to be sufficient when a cold stimulus ap-
plied by a metal rod immersed in ice water (7 s, 0°C) was
not to be distinguished from a mechanical stimulus. Dur-
ing the whole duration of the block subjects were able to
feel pin-prick stimulation as painful sharp pricking, which
was interpreted as maintained C-fiber function [49].
When nerve block was established 70 μl of a 100 nM
ATX-II containing sterile buffer solution was injected and
subjects were asked to rate pain-like and itch-like sensa-
tions for 10 min before removal of the block and 10 and
20 min thereafter together with ratings of cold-evoked
pain (0°C, 7 s, Figure 7). For the NRS curves of each
subject the area under the curve (AUC) was calculated
(Figure 7a+ b, bar graphs).
Chemicals
A 5, 25 or 100 nM recombinant ATX-II (Anemonia sul-
cata toxin, Alomone Labs, Jerusalem, Israel or Sigma-
Aldrich, USA) solution was prepared in saline solution
(either extracellular recording solution or sterile bufferfor injections, which was additionally sterile filtered).
TTX (Tetrodotoxin, Biotrend AG, Wangen, Switzerland)
was diluted to a final concentration of 500 nM in the
extracellular recording solution. For recordings with β4-
peptide an internal solution containing 100 μM β4-
peptide (KKLITFILKKTREK, PSL GmbH, Heidelberg,
Germany, [50]) was prepared and stored on ice during
the process of the experiments.Statistics
All data are presented as mean± standard error of the
mean (SEM). Paired-sample T-test was used for statistical
analysis of DRG paired patch clamp recordings and for
N1E115 and DRG activation and steady-state fast inactiva-
tion analysis. For temperature effect analysis non-paired
Mann Whitney U-test was used for group comparison.
For experiments performed on HEK cells and preincu-
bated DRGs independent-sample T-test was used to
test for significance. For psychophysics experiments
a Wilcoxon matched pairs test was used for intra-individual
comparisons and Mann Whitney U-test for the comparison
of groups. For RT-qPCR one-tailed Mann Whitney U-test
was used for group comparison. Statistical significances are
indicated with * for p <0.05, ** for p <0.01 and *** for
p <0.001.Additional files
Additional file 1: Figure S1. Activation properties of resurgent currents
of large diameter DRGs. (a). Resurgent current–voltage curve normalized
to peak inward TTXs resurgent currents for large diameter DRGs. (b).
Relative resurgent conductance of peak inward TTXs resurgent currents,
pre (black squares) and post (pink squares) ATX-II application at 22°C
(filled squares, n = 8) and 30°C (open squares n = 14) for large diameter
DRGs. Midpoints of activation of relative resurgent conductance were
retrieved from a Boltzmann fit and are not significantly different (control
22°C: -57.5 ± 1.4 mV, post ATX-II 22°C: -57.5 ± 1.7 mV, control 30°C:
-53.9 ± 1.2 mV, post ATX-II 30°C: -57.7 ± 1.7 mV; Wilcoxon matched pairs
test for ATX-II effect: 22°C p= 0.889, 30°C p =0.099; Mann–Whitney-U-test
for temperature dependent effect: pre 22°C vs. 30°C p = 0.054, post 22°C
vs. 30°C p= 0.758).
Additional file 2: Figure S2. ATX-II shifts voltage-dependence of
activation and steady-state fast inactivation to more hyperpolarized
potentials in both large and small DRGs. (a). Voltage-dependence of
activation and steady-state fast inactivation of large (left, n = 11–17) and
small (right, n = 21-22) DRGs. Vhalf of activation of both cell types is
shifted due to exposure to ATX-II significantly (large control:
-42.6 ± 1.1 mV, ATX-II: -45.0 ± 0.94 mV, p < 0.01, small control:
-34.9 ± 1.0 mV, ATX-II: -40.7 ± 0.8 mV, p < 0.001, paired-sample T-test)
whereas slope is not significantly different from control (large control:
2.76 ± 0.22 ATX-II: 2.96 ± 0.23, p = 0.23, small control: 5.66 ± 0.3, ATX-II:
5.7 ± 0.4, p = 0.84, paired-sample T-test). For inactivation, Vhalf of both cell
types is shifted significantly (p large < 0.001, p small < 0.001, paired-
sample T-test), Vhalf for steady-state inactivation was for large DRGs
control: -62.5 ± 1.2 mV, ATX-II: -66.8 ± 1.2 mV, p < 0.001, small DRGs
control: - 74.7 ± 2.4 mV, ATX-II: - 80.5 ± 2.0 mV, p < 0.001, paired-sample T-
test). (b) and (c): Results from a double exponential fit to current decay of
traces evoked by the activation protocol from large and small DRGs. (b).
Fractional A1 (A1/(A1 + A2)) is shown as a function of voltage. (c). Fast τ1
and slow τ2 time constants of current decay are shown as a function of
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http://www.molecularpain.com/content/8/1/69voltage. We could not detect any significant changes in the decay time
constants of small or large DRGs.
Additional file 3: Figure S3. ATX-II fails to evoke resurgent currents in
small diameter DRGs also at higher concentrations. (a) Recordings of
small DRGs after application of 25 nM ATX-II to the bath solution.
Representative resurgent current traces, shown on a magnified time scale
on the right. There was no resurgent current detectable although
persistent and tail currents are induced by 25 nM ATX-II. (b) TTXs peak
current at the time point at which resurgent currents would be expected
as a function of voltage. While there is nearly no tail current under
control conditions (black squares), application of 25 nM ATX-II increased
tail currents, albeit not significantly (pink squares, not significant in a
paired-sample T-test, n = 5). (c) Same test setting as shown in (b) but tail
currents were excluded in the analysis, leaving only the first part of the
slowly declining persistent current detectable (* p < 0.05, paired-sample
T-test). (d) Persistent current seems to be affected by application of 25nM
ATX-II (pink squares, * p < 0.05, paired-sample T-test, n = 5).Abbreviations
Nav: Voltage-gated sodium channel; DRGs: Dorsal root ganglion sensory
neurons; TTX: Tetrodotoxin; PEPD: Paroxysmal extreme pain disorder; RT-
qPCR: Real time quantitative polymerase chain reaction; ATX-II: Sea anemone
toxin II; AUC: Area under the curve; CGRP: Calcitonine gene-related peptide;
AP: Action potential; ns: Statistically not significant.
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